Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation

• Published in: Blood 2011-11, Vol.118 (21), p.1990-1990
• Main Authors: Yhim, Ho-Young, Kim, Kihyun, Kim, Jin Seok, Kang, Hye Jin, Kim, Jeong-A, Min, Chang-Ki, Bae, Sung Hwa, Park, Eunkyung, Yang, Deok-Hwan, Suh, Cheolwon, Kim, Min Kyoung, Mun, Yeung-Chul, Eom, Hyeon Seok, Shin, Ho Jin, Yoon, Hwi-Joong, Kwon, Jung Hye, Lee, Jae Hoon, Kim, Yang Soo, Yoon, Sung-Soo, Kwak, Jae-Yong
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V118.21.1990.1990

Abstract 1990 Autologous stem cell transplantation (ASCT) is a standard of care for younger multiple myeloma patients (pts). However, nearly all pts undergoing ASCT will relapse and require salvage therapy. Several investigators have reported 2nd ASCT might be a feasible and effective treatment modality in some pts. However, these studies contained small number of pts with 2nd ASCT and did not compare with outcomes of salvage therapy using novel agents. Thus, the aims of this study are to investigate outcomes of 2nd ASCT in pts relapsed after front-line ASCT and identify the impact of 2nd ASCT compared to modern systemic therapy in the novel agent era. To minimize the heterogeneity between the 2 groups, matched-pair design was chosen. The data of 48 pts between 1998 and 2010 with 2nd ASCT after relapse of front-line ASCT identified from web-based registry (www.myeloma.or.kr) were analyzed. Pts with tandem ASCT or salvage allo-SCT were excluded. The goal of this study was to perform a matched-pair analysis, each patient with 2nd ASCT was matched to three pts from a cohort of 517 pts treated with systemic chemotherapy after relapse of prior ASCT. The pts were matched for 9 potential prognostic factors: age at relapse (